Nasus Pharma Ltd. NSRX
3.48
0.00
0.00%
as of 25 Sep
- Market cap
- $40.8M
- P/E
- —
Follow NSRX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
8.77 | 2.24 | 0.06 | 0.12 |
+1 more quarter Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 401.10% | 251.32% | |
Debt/Equity |
0.00 | 0.00 | (0.59) | (0.56) | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | — | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(6.04) | (4.93) | (0.43) | (0.66) | |
Working Capital |
10.91 | 2.69 | (4.66) | (3.47) | |
Capital Expenditures |
0.00 | (0.01) | — | 0.00 | |
Net Current Asset Value |
10.86 | 2.62 | (4.66) | (3.47) | |
| Other line items | |||||
Quick Ratio |
5.63 | 0.60 | 0.05 | 0.08 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Payables |
0.50 | — | — | — | |
Average Assets |
6.45 | — | — | — | |
Average Common Equity |
3.60 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates